STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...

University of Chicago researchers have developed a liquid biopsy test based on modification patterns in microbiome-derived cell-free RNA that predicts colorectal cancer (CRC) with greater accuracy ...

A Northwestern Medicine study published in the Journal of Clinical Investigation has uncovered a connection between a well-known cancer-related protein and a major RNA modification process, which may ...

This study is led by Professor XiaoqinLiu (Peking University Institute of Advanced Agricultural Sciences, Shandong Laboratory of Advanced Agriculture Sciences, Shangdong, China). The authors explored ...